# Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

> **NCT04274816** · PHASE1 · COMPLETED · sponsor: **A.J.M. van den Eertwegh** · enrollment: 13 (actual)

## Conditions studied

- Cutaneous Melanoma

## Interventions

- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT04274816
- **Lead sponsor:** A.J.M. van den Eertwegh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-10
- **Primary completion:** 2014-02-27
- **Final completion:** 2014-02-27
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04274816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04274816, "Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04274816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*